title: Hepatocellular carcinoma: sorafenib: for once age is not an issue.
abstract: Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions.
authors.affiliation: University Clinic of Visceral Surgery and Medicine, Department of Hepatology, Inselspital, CH-3010 Bern, Switzerland.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Dufour